Get support
Call the number below to get directly connected to the local MND association in your State
Australia Map
1800 777 175
9am to 4:30pm Monday to Friday

(MND services in the ACT are provided by MND NSW)

Building 4, Gladesville Hospital, Victoria Road, Gladesville NSW 2111

Post: Locked Bag 5005,Gladesville NSW 1675

T: 1800 777 175

Visit website Send a message

66 Hughes Street, Mile End SA 5031

Post: PO Box 2087 Hilton Plaza SA 5033

T: 1800 777 175

Visit website Send a message

Building 4, Gladesville Hospital,Victoria Road, Gladesville NSW 2111

Post: Locked Bag 5005,Gladesville NSW 1675

T: 1800 777 175

Visit website Send a message

(MND services in Tasmania are provided by MND Victoria)

265 Canterbury Rd, Canterbury Vic 3126

Post: PO Box 23, Canterbury 3126

T: 1800 777 175

Visit website Send a message

(MND services in the NT are provided by MND NSW)

Building 4, Gladesville Hospital, Victoria Road, Gladesville NSW 2111

Post: Locked Bag 5005, Gladesville NSW 1675

T: 1800 777 175

Visit website Send a message

265 Canterbury Rd, Canterbury Vic 3126

Post: PO Box 23, Canterbury 3126

T: 1800 777 175

Visit website Send a message

1/89 Factory Road, Oxley QLD 4075

Post: PO Box 470, Inala QLD 4077

T: 1800 777 175

Visit website Send a message

Unit 1, 184 Raleigh Street, Carlisle WA 6101

Post: as above

T: 1800 777 175

Visit website Send a message

Search

Donate

Clinical trial update: Lighthouse II study discontinued

08 April 2025

Following the analysis of interim results of the Lighthouse II Phase 3 clinical trial, the trial has been terminated. MND Australia understands that this information is disappointing and distressing for the MND community in Australia. 

This clinical trial was designed to include an interim analysis while the trial was still underway to assess whether the drug, Triumeq, was showing any benefit. 

Unfortunately, this interim analysis found that there was no difference in survival measures between those taking the active ingredient and those who were taking the placebo and this indicates that Triumeq is not believed to be beneficial for people with MND. Following these results, the decision was made to stop the trial.

A full data analysis will be undertaken following this decision. 

You can read more about this decision here.